Diagnostic Challenges of CD4+/CD56+/CD123+ hematological neoplasms

Thiago, Leandro S.; Sandes, Alex Freire

doi:10.1590/abd1806-4841.20132799

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the lineage‐commitment of blast cells cannot be defined after completing the mandatory panel, additional tubes should be performed to evaluate the less frequent myeloid lineages (pDC, basophils, and mast cell s ). BPDCN could be suspected in CD4 + /CD56 + cases that lack expression of CD34 and lineage‐specific markers ( Cy MPO, CD64, CD14, CD61, Cy CD3, Cy CD79a, and CD19) . BPDCN can also express CD36 and NG2 .…”

Section: Acute Myeloid Leukemia Panelmentioning

confidence: 99%

First proposed panels on acute leukemia for four-color immunophenotyping by flow cytometry from the Brazilian group of flow cytometry-GBCFLUX

et al. 2014

Self Cite

View full text Add to dashboard Cite

Multiparameter flow cytometry is a highly sensitive, fast, and specific diagnostic technology with a wide range of applicability in hematology. Although well-established eight-color immunophenotyping panels are already available, most Brazilian clinical laboratories are equipped with four-color flow cytometer facilities. Based on this fact, the Brazilian Group of Flow Cytometry (Grupo Brasileiro de Citometria de Fluxo, GBCFLUX) for standardization of clinical flow cytometry has proposed an antibody panel designed to allow precise diagnosis and characterization of acute leukemia (AL) within resource-restricted areas. Morphological analysis of bone marrow smears, together with the screening panel, is mandatory for the primary identification of AL. The disease-oriented panels proposed here are divided into three levels of recommendations (mandatory, recommendable, and optional) in order to provide an accurate final diagnosis, as well as allow some degree of flexibility based on available local resources and patient-GBCFLUX Acute Leukemia Subcommittee: Bacal NS (Hospital

show abstract

Section: Acute Myeloid Leukemia Panelmentioning

confidence: 99%